Product Data Sheet

CX-4945 (Silmitasertib)

Catalog No. A11060

main product photo
CX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells.
Adooq's CX-4945 (Silmitasertib) has been cited by 14 publications
  • Michael Ohene-Nyako, .et al. , ASN Neuro, 2023, Jan-Dec;15:17590914231158218 PMID: 36890725
  • Xixi Zhao, .et al. , Cancer Res, 2022, Jun 6;82(11):2185-2195 PMID: 35385574
  • Janeen H. Trembley, .et al. , Biomedicines, 2021, May; 9(5): 571 PMID: 34070147
  • Tianzhi Huang, .et al. , Mol Cell, 2021, Mar 18;81(6):1276-1291 PMID: 33539787
  • M Afzal, .et al. , Molecular and Cellular Biochemistry, 2020, 470, pages131-143
  • Zaman MS, .et al. , Biometals, 2019, Oct 3 PMID: 31583500
  • Fukumoto Y, .et al. , Biochem Biophys Res Commun, 2019, Sep 17;517(2):310-316 PMID: 31353086
  • Fukumoto Y, .et al. , Biochem Biophys Res Commun, 2018, Oct 2;504(2):380-386 PMID: 29902452
  • ST Ribeiro, .et al. , Leukemia, 2017, Jul; 31(7): 1603-1610 PMID: 27899804
  • Valentina Gandin, .et al. , Nat Commun, 2016, 7: 11127 PMID: 27040916
  • Ampofo E, .et al. , Eur Surg Res, 2016, 57(1-2):111-24 PMID: 27287005
  • Emmanuel Ampofo, .et al. , Thromb Res., 2015, Nov;136(5):996-1006 PMID: 26381437
  • Emmanuel Ampofo, .et al. , Biochim Biophys Acta., 2015, Oct;1852(10 Pt A):2123-36 PMID: 26189586
  • A. Margarida Gomes, .et al. , Haematologica, 2014, 99(6): 1062-1068 PMID: 24561792
    • Chemical Information
    Catalog Num A11060
    M. Wt 349.8
    Formula C19H12ClN3O2
    Purity >98%
    Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
    CAS No. 1009820-21-6
    Synonyms Silmitasertib, CX 4945, CX4945
    SMILES C1=CC(=CC(=C1)Cl)NC2=C3C=CN=CC3=C4C=CC(=CC4=N2)C(=O)O
    Storage

    Store lyophilized at -20ºC, keep desiccated.
    In lyophilized form, the chemical is stable for 36 months.
    In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
    Biological Activity
    Discription CX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells.
    Targets
    Target Value
    Solubility
    In vitro (25°C) DMSO 14 mg/mL (40.02 mM)
    Water Insoluble
    Ethanol Insoluble
    In vivo 1% CMC Na 28 mg/mL
    * <1 mg/ml means slightly soluble or insoluble.
    * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
    Preparing Stock Solutions
    Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
    0.1 mM 28.59 mL 142.94 mL 285.88 mL
    0.5 mM 5.72 mL 28.59 mL 57.18 mL
    1 mM 2.86 mL 14.29 mL 28.59 mL
    5 mM 0.57 mL 2.86 mL 5.72 mL
    RETURN POLICY
    Adooq’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
    SHIPPING AND STORAGE
    Adooq products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Adooq Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Adooq products are stable under the recommended conditions.